Department of Surgery, Clinical Sciences Lund, Skåne University Hospital, Lund University, Lund, Sweden.
Clin Transl Oncol. 2020 Dec;22(12):2170-2174. doi: 10.1007/s12094-020-02372-0. Epub 2020 May 23.
Pancreatic cancer has the highest mortality amongst all major organ cancers. Early detection is key to reduce deaths related to pancreatic cancer. However, early detection has been challenged by the lack of non-invasive biomarkers with enough sensitivity and specificity to allow for screening. The gold standard is still carbohydrate antigen (CA 19-9), against which all new biomarkers must be evaluated. In this paper, we describe recent progress in the development of new pancreatic cancer biomarkers, focusing on proteins, metabolites, and genetic and epigenetic biomarkers. Although several promising biomarkers have been identified, they are all derived from retrospective studies and additional prospective studies are needed to confirm their clinical validity.
胰腺癌是所有主要器官癌症中死亡率最高的癌症。早期发现是降低胰腺癌相关死亡的关键。然而，由于缺乏足够敏感性和特异性的非侵入性生物标志物，早期检测一直具有挑战性，无法进行筛查。目前的金标准仍然是碳水化合物抗原（CA 19-9），所有新的生物标志物都必须针对该抗原进行评估。在本文中，我们描述了新的胰腺癌生物标志物的最新进展，重点介绍了蛋白质、代谢物以及遗传和表观遗传生物标志物。尽管已经确定了几种有前途的生物标志物，但它们都是从回顾性研究中得出的，还需要进行额外的前瞻性研究来确认它们的临床有效性。
